Litigation-Aware Prosecution: Turn Your Drug Patent Portfolio Into a Competitive Assertion Asset
Most pharma teams still treat patent strategy like a filing exercise: draft, file, wait, and hope the claims hold up later. But in todays environmentwhere …

Hospitals are sitting on a quiet competitive advantageand many are ignoring it.
In the pharmaceutical market, timing is everything. Patent cliffs dont just change drug prices; they reshape formularies, procurement leverage, and patient access. Yet a gr…

Generic launches dont happen. They arriveon a timeline you can model.
Most teams treat generic entry as a calendar event: watch the FDA, wait for the label, then react when the market shifts. Thats expensiveand late.
If youre competing in branded pharm…

Most people hunt patents. Few people actually read the Orange Book like a map.
If youre in pharma business development, licensing, BD strategy, or competitive intelligence, youve probably seen the same pattern play out: teams chase obvious targetspubli…

Biotech investors love pipeline value, but most portfolio rankings still miss the point.
A company can have a long list of programs and still be value-destructivebecause the timing of cash flows, the probability of technical success, and the economics …

Biopharma is entering a new kind of patent cliffnot just for revenue, but for talent.
When blockbuster exclusivities expire, the industry doesnt just lose market share. It loses momentum. Teams get reorganized. Budgets tighten. Hiring freezes appear. A…

Overstocking branded drugs isnt just a balance-sheet problemits a patent-timing problem.
For wholesalers, the margin story is familiar: buy right, ship fast, manage service levels. But the real risk often hides in plain sightinside the patent calenda…

Big Pharma doesnt just feel a patent cliffit hires like it does.
When blockbuster exclusivity ends, the industrys first instinct isnt always a press release. Its a staffing signal: new roles posted, teams reorganized, and specialized talent pulled into…

Biosimilar sourcing isnt a procurement problemits a patent strategy problem.
Most teams treat biosimilar switching like a pricing exercise: identify the lowest acquisition cost, update formularies, and move on. But in biosimilars, the lowest price can …

Old Drugs. New Prices. The Pharma Playbook for Repurposed Premiums.
Theres a quiet shift happening across healthcareand it rarely makes headlines until the bill hits.
A growing number of medicines that were once considered off-patent, legacy, or simply…